Lpath Says Pfizer Notice Includes Option for iSONEP License

Lpath, Inc.

, the industry leader in bioactive-lipid-targeted therapeutics, has received notice from Pfizer Inc. that Pfizer is currently seeking to divest certain ophthalmology R&D assets, including Pfizer's exclusive option for a worldwide license to develop and commercialize Lpath's iSONEP™. Lpath has presented an offer to Pfizer to reacquire these rights, and Lpath believes that a number of third parties may have an interest in acquiring these rights as well. iSONEP is currently being studied by Lpath in a Phase 2 clinical trial as both monotherapy and adjunctive therapy in wet-AMD patients. A data read-out on the study is expected in the third quarter of 2014.